https://www.selleckchem.com/products/ml390.html
3%), such as hypercholesterolemia, arterial hypertension, diabetes mellitus,and depression. Moreover, 52.3% were treatment-experienced patients with up to two treatments prior to raltegravir. Across thestudy time points, there was a reduction in the viral load and improvement in CD4 counts in both the treatment-naïve and treatment-experienced subgroups. Continuing users of raltegravir reported high treatment satisfaction (55.4 ± 7.2 points). Raltegravir-based regimens seem like a valid therapeutic option in heterogeneous populations of HI
Gefällt mir
Kommentar
Teilen
